Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties
The impressive results of the RECOVERY trial established that a moderate dose of dexamethasone (6 mg daily for 10 days) reduced mortality in hospitalised patients with COVID-19 and respiratory failure who required therapy with supplemental oxygen or mechanical ventilation.1 The data also indicated that dexamethasone might increase mortality in hospitalised patients who were not receiving oxygen….